StemCell Therapy

LINDA A. JOHNSON, AP Medical Writer 1:09 p.m. ET April 14, 2017

Eli Lilly made the list.(Photo: Joe Vitti/IndyStar)Buy Photo

Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmakers second drug development setback since November.

The Food and Drug Administration said in a letter to the company that it needed more information about the drugs safety and the best doses, Lilly said Friday in a statement.

Lilly said it disagrees with FDAs conclusions but will work with the agency on a plan to eventually get the drug, baracitinib, approved for U.S. patients.

In November, Lillys experimental medicine solanezumab flopped in a closely watched test in patients with mild Alzheimers disease, after having already failed in testing in patients with more advanced Alzheimers.

The arthritis drug, which has the proposed brand name Olumiant and was approved for use in Europe in February, was expected to be a big seller in part because most other new rheumatoid arthritis drugs are injected, making them less appealing for patients.

Christi Shaw, president of the Lilly division that developed the drug, said the company remains confident in the drugs ability to safely treat moderate and severe rheumatoid arthritis.

About 23 million people worldwide, three-fourths of them women, have rheumatoid arthritis, a chronic disorder in which the immune system attacks the bodys tissues. It causes painful swelling and progressive destruction of joints, which can leave them deformed and, in severe cases, lead to disability. It can also damage other body parts, including the skin, eyes, lungs, heart and blood vessels.

Eli Lilly & Co. and Incyte Corp., its partner in developing baracitinib, applied for FDA approval of the drug in January 2016. Normally the review process takes 10 months, but this January, FDA said it needed three additional months to review more information. Still, drug industry analysts as recently as this week were advising clients that approval of baracitinib was likely.

Despite the setback, Lilly reaffirmed its 2017 financial forecasts Friday, for earnings per share of $2.69 to $2.79, excluding one-time items, and revenue between $21.8 billion and $22.3 billion. It said Incyte, which is based in Wilimington, Delaware, was evaluating the rejections impact on its position and would update investors when it reports first-quarter results, likely in mid-May. Lilly is expected to report its quarterly results on April 25.

Read or Share this story: http://indy.st/2pf6Ruj

See the rest here:
Feds reject Lilly's rheumatoid arthritis pill - Indianapolis Star

This entry was posted on April 16, 2017 at 9:47 pm and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |